查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1609088

分子腫瘤學診斷市場：按產品、技術、癌症類型和最終用戶分類 - 全球預測 2025-2030

Molecular Oncology Diagnostics Market by Product (Instruments, Reagents), Technology (Chips & Microarrays, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT)), Cancer Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

分子腫瘤診斷市場2023年估值為88.4億美元，預計2024年將達到98.8億美元，複合年成長率為11.83%，到2030年將達到193.6億美元。

分子腫瘤學診斷是一個快速發展的領域，專注於透過基因組學、蛋白質組學和代謝體學等分子技術來檢測和表徵癌症。這些診斷的需求源於對早期檢測、改善預後、改善治療結果以及精確和個人化的癌症治療策略的需要。應用範圍從識別與癌症相關的特定基因突變到監測正在進行的治療的有效性。最終用途範圍涵蓋醫院、診斷實驗室和研究機構，並依賴次世代定序(NGS) 和聚合酵素鏈鎖反應(PCR) 等先進技術。

主要市場統計
基準年[2023] 88.4億美元
預計年份 [2024] 98.8億美元
預測年份 [2030] 193.6億美元
複合年成長率（%） 11.83%

根據市場洞察，分子腫瘤診斷的成長是由癌症發生率增加、分子診斷技術進步以及精準醫療需求不斷成長所推動的。主要企業之間的策略聯盟和合併也正在推動市場擴張。開拓具有成本效益且更容易獲得的診斷工具存在機會，這些工具可以開拓醫療基礎設施不足的新興市場。人工智慧和機器學習在診斷過程中的整合對於惡性的早期、準確檢測具有廣闊的前景。然而，挑戰依然存在，包括先進診斷技術的高成本、資料解釋的複雜性以及阻礙快速進入市場的嚴格監管要求。

為了利用這個機會，公司應該專注於非侵入性液態切片的研究和開發，以擴大可以預測患者對特定癌症治療反應的伴同性診斷的範圍。最佳創新領域包括開發照護現場解決方案和增強生物資訊學以有效分析複雜的癌症基因組資料。市場競爭激烈且充滿活力，重點是採用新技術和策略聯盟來加強市場地位。儘管面臨挑戰，但投資並優先考慮創新以克服這些限制的公司可能會獲得競爭優勢，從而導致分子腫瘤診斷市場的業務顯著成長。

市場動態：快速發展的分子腫瘤診斷市場的關鍵市場洞察

分子腫瘤學診斷市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 癌症患者增加和人口老化
    • 對自動化和先進診斷技術的需求不斷增加
    • 有利的醫療報銷和個人化醫療的趨勢
  • 市場限制因素
    • 分子腫瘤學診斷測試相關的高成本
  • 市場機會
    • 持續投資癌症診斷藥物的研發活動
    • 分子生物學和生物技術的技術進步
  • 市場挑戰
    • 嚴格的監管障礙加上分子診斷技術缺乏一致的標準

波特五力策略工具引領分子腫瘤診斷市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解分子腫瘤診斷市場的外部影響

外部宏觀環境因素在塑造分子腫瘤診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解分子腫瘤診斷市場的競爭格局

對分子腫瘤診斷市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣分子腫瘤診斷市場供應商績效評估

FPNV定位矩陣是評估分子腫瘤診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規分類子腫瘤診斷市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對分子腫瘤診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率增加和人口老化
      • 對自動化和先進診斷技術的需求不斷增加
      • 有利的醫療報銷和個人化醫療的趨勢
    • 抑制因素
      • 分子腫瘤學診斷測試相關的高成本
    • 機會
      • 持續投資腫瘤診斷的研發活動
      • 分子生物學和生物技術的技術進步
    • 任務
      • 分子診斷技術的嚴格監管障礙和缺乏一致的標準
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章分子腫瘤學診斷市場：依產品

  • 裝置
  • 試劑

第7章分子腫瘤學診斷市場：依技術分類

  • 晶片和微陣列
  • 原位雜合技術
  • 恒溫核酸增幅技術（INAAT）
  • 質譜分析
  • 連接複用
  • PCR
  • 定序
  • 透過轉錄進行擴增

第8章按癌症類型分類的分子腫瘤學診斷市場

  • 血癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 攝護腺癌

第9章分子腫瘤學診斷市場：依最終用戶分類

  • 診斷中心
  • 醫院

第10章美洲分子腫瘤診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區分子腫瘤診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲分子腫瘤診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • Biocept, Inc.
  • BIOMERIEUX SA
  • Danaher Corporation
  • DiaSorin Molecular LLC
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenMark Saglik
  • Hologic, Inc.
  • Illumina, Inc.
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • OncoCyte Corporation
  • PathAI, Inc.
  • Personal Genome Diagnostics Inc.
  • QIAGEN NV
  • Siemens AG
  • Sysmex Asia Pacific Pte Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFE6

The Molecular Oncology Diagnostics Market was valued at USD 8.84 billion in 2023, expected to reach USD 9.88 billion in 2024, and is projected to grow at a CAGR of 11.83%, to USD 19.36 billion by 2030.

Molecular Oncology Diagnostics is a rapidly evolving field focused on the detection and characterization of cancer through molecular-based techniques, such as genomics, proteomics, and metabolomics. The necessity for these diagnostics stems from the need for precise and personalized cancer treatment strategies, improving early detection, prognosis, and therapeutic outcomes. Applications range from identifying specific genetic mutations associated with cancer to monitoring the effectiveness of ongoing treatments. The end-use scope spans across hospitals, diagnostic laboratories, and research institutes, relying on advanced technologies like next-generation sequencing (NGS) and polymerase chain reaction (PCR).

KEY MARKET STATISTICS
Base Year [2023] USD 8.84 billion
Estimated Year [2024] USD 9.88 billion
Forecast Year [2030] USD 19.36 billion
CAGR (%) 11.83%

Market insights reveal that the growth of Molecular Oncology Diagnostics is driven by increased cancer prevalence, advancements in molecular diagnostics technology, and the rising demand for precision medicine. Strategic partnerships and mergers among key players are also fostering market expansion. Opportunities lie in developing cost-effective and more accessible diagnostic tools, which could tap into emerging markets with insufficient healthcare infrastructure. The integration of AI and machine learning in diagnostic processes holds promising potential for early and more accurate detection of malignancies. However, challenges persist, including the high costs of advanced diagnostic techniques, the complexity of data interpretation, and stringent regulatory requirements that can impede rapid market entry.

To capitalize on opportunities, companies should focus on R&D in non-invasive liquid biopsies and expand the scope of companion diagnostics that can predict patient responses to specific cancer treatments. Best areas of innovation include the development of point-of-care diagnostic solutions and the enhancement of bioinformatics to analyze complex cancerous genomic data efficiently. The market is competitive yet dynamic, emphasizing both the adoption of novel technologies and strategic collaborations to strengthen market position. Despite the challenges, companies that invest in overcoming these limitations and prioritize innovation are likely to gain a competitive advantage, leading to substantial business growth in the Molecular Oncology Diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Oncology Diagnostics Market

The Molecular Oncology Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer cases and aging population
    • Rising need for automated and advanced diagnostic techniques
    • Favorable health reimbursement and the trend toward personalized medicine
  • Market Restraints
    • High cost associated with molecular oncology diagnostics test
  • Market Opportunities
    • Ongoing investments in R&D activities in oncology diagnostics
    • Technological advancements in molecular biology and biotechnology
  • Market Challenges
    • Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Oncology Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Oncology Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Oncology Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Oncology Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Oncology Diagnostics Market

A detailed market share analysis in the Molecular Oncology Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Oncology Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Oncology Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Oncology Diagnostics Market

A strategic analysis of the Molecular Oncology Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Oncology Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, Biocept, Inc., BIOMERIEUX SA, Danaher Corporation, DiaSorin Molecular LLC, Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., GenMark Saglik, Hologic, Inc., Illumina, Inc., Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OncoCyte Corporation, PathAI, Inc., Personal Genome Diagnostics Inc., QIAGEN N.V., Siemens AG, Sysmex Asia Pacific Pte Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Oncology Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments and Reagents.
  • Based on Technology, market is studied across Chips & Microarrays, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Mass Spectrometry, Multiplex, PCR, Sequencing, and Transcription Mediated Amplification.
  • Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End User, market is studied across Diagnostic Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases and aging population
      • 5.1.1.2. Rising need for automated and advanced diagnostic techniques
      • 5.1.1.3. Favorable health reimbursement and the trend toward personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with molecular oncology diagnostics test
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing investments in R&D activities in oncology diagnostics
      • 5.1.3.2. Technological advancements in molecular biology and biotechnology
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Molecular Oncology Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents

7. Molecular Oncology Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Chips & Microarrays
  • 7.3. In Situ Hybridization
  • 7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.5. Mass Spectrometry
  • 7.6. Multiplex
  • 7.7. PCR
  • 7.8. Sequencing
  • 7.9. Transcription Mediated Amplification

8. Molecular Oncology Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Blood Cancer
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Kidney Cancer
  • 8.7. Liver Cancer
  • 8.8. Lung Cancer
  • 8.9. Prostate Cancer

9. Molecular Oncology Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals

10. Americas Molecular Oncology Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Molecular Oncology Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Oncology Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. Bayer AG
  • 4. Becton, Dickinson and Company
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biocartis NV
  • 7. Biocept, Inc.
  • 8. BIOMERIEUX SA
  • 9. Danaher Corporation
  • 10. DiaSorin Molecular LLC
  • 11. Enzo Biochem, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GenMark Saglik
  • 14. Hologic, Inc.
  • 15. Illumina, Inc.
  • 16. Leica Biosystems Nussloch GmbH
  • 17. Myriad Genetics, Inc.
  • 18. NeoGenomics Laboratories
  • 19. OncoCyte Corporation
  • 20. PathAI, Inc.
  • 21. Personal Genome Diagnostics Inc.
  • 22. QIAGEN N.V.
  • 23. Siemens AG
  • 24. Sysmex Asia Pacific Pte Ltd.
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CHIPS & MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTIPLEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 200. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023